Clinical Trial Update: Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing rabeprazole extended-release 50 mg to ranitidine 150 mg for maintenance of healing in erosive gastroesophageal reflux disease completed,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Rabeprazole Extended Release 50 mg (rabeprazole)
• Ranitidine 150 mg (ranitidine)

Snippet

Sponsor: Eisai Inc. | Conditions: Gastroesophageal Reflux Disease (GERD) | Phase 3 | Status: COMPLETED | Results posted: 2015-11-16